Tag: First generation antipsychotics

The prevalence of tardive dyskinesia (TD), a potentially permanent movement disorder, is estimated to be around 25.3% among patients treated with antipsychotics [1.4.3]. Answering 'What are the permanent side effects of antipsychotics?' is vital for patient safety and informed treatment decisions.

Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease [1.3.3, 1.3.7]. The group of drugs most frequently used for drug-induced Parkinsonism are antipsychotics, particularly typical or first-generation antipsychotics [1.2.3, 1.2.4].

The dopamine hypothesis of schizophrenia, first proposed in the 1960s, suggests that certain symptoms are linked to disturbed dopamine signaling in the brain. For individuals with this condition, understanding what dopamine drugs are used for schizophrenia is crucial, as medication is a cornerstone of managing psychotic symptoms.

Studies show that a high cumulative lifetime dose of antipsychotics is associated with poorer cognitive performance [1.7.4]. The critical question for many patients and clinicians is, do antipsychotics affect memory, and what does the evidence say about this complex interaction?

Studies show that exposure to any antipsychotic (AP) medication can confer an increased risk for dementia [1.2.3]. The question, **do antipsychotics reduce cognitive function**, is complex, with effects varying by drug type, dosage, and the patient's underlying condition. This article examines the nuanced mechanisms and outcomes.

Antipsychotics are the primary treatment for schizophrenia, yet up to 60% of patients still experience significant negative symptoms. The question of whether **antipsychotics worsen negative symptoms** is complex, as distinguishing medication side effects from the core illness is challenging. This article investigates the relationship between antipsychotic use and negative symptoms, exploring the differences between medication classes and new research directions.

Developed in 1950, chlorpromazine was the first antipsychotic medication, revolutionizing psychiatric care. But in an era of newer drugs, **do people still use chlorpromazine?** This pioneering medication remains in use for specific conditions, though less commonly than in the past.

In 2020, chlorpromazine, the generic form of Thorazine, was prescribed to approximately half a million people in the United States [1.2.2]. For those seeking alternatives, it's essential to understand what drug is similar to Thorazine and the available options.

The discontinuation of fluphenazine decanoate (Modecate) around 2018 was primarily due to manufacturing difficulties and unpredictable supplies of its active pharmaceutical ingredient [1.2.2, 1.4.3]. This article delves into why was fluphenazine discontinued and the impact on patients.

An estimated 20% to 50% of patients treated with antipsychotics develop tardive dyskinesia (TD), a medication-induced movement disorder [1.4.2]. So, **which medication is most likely to cause tardive dyskinesia?** The highest risk is associated with older, first-generation antipsychotics [1.2.6, 1.2.7].